Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Melanoma 5 Colorectal Neoplasms 3 Thyroid Neoplasms 2 Ovarian Neoplasms 2 Glioma 2 Endometrial Neoplasms 2 Carcinoma, Non-Small-Cell Lung 2 Uterine Neoplasms 1 Uterine Cervical Neoplasms 1 Urinary Bladder Neoplasms 1 Stomach Neoplasms 1 Rectal Neoplasms 1 Prostatic Neoplasms 1 Pancreatic Neoplasms 1 Neurofibromatosis 1 1 Neoplasm Metastasis 1 Multiple Myeloma 1 Lymphoma 1 Lymphatic Metastasis 1 Lung Neoplasms 1 Hereditary Sensory and Autonomic Neuropathies 1 Hematologic Neoplasms 1 Fallopian Tube Neoplasms 1 Esophageal Neoplasms 1 Colonic Neoplasms 1 Carcinoma, Renal Cell 1 Carcinoma, Hepatocellular 1 Breast Neoplasms 1 Brain Neoplasms 1 Biliary Tract Neoplasms 1

Interventions

Cisplatin 5 Gemcitabine 4 Oxaliplatin 2 Irinotecan 2 Fluorouracil 2 Capecitabine 2 Bevacizumab 2 zanidatamab 1 toripalimab 1 pembrolizumab 1 niraparib 1 neratinib 1 ivosidenib 1 futibatinib 1 fludarabine 1 envafolimab 1 encorafenib 1 durvalumab 1 binimetinib 1 Trastuzumab 1 Pemetrexed 1 Nivolumab 1 Folfox protocol 1 Docetaxel 1 Cyclophosphamide 1 Cetuximab 1 Carboplatin 1 Actigraphy 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Biliary Tract Neoplasms × binimetinib × 30 days × Clear all

NCT05615818 2026-05-19

SAFIR-ABC10

UNICANCER

Phase 3 Recruiting

Gastrointestinal

Biliary Tract Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡